Abeona Therapeutics misses Q2 revenue targets, shares fall 14% amid Zevaskyn rollout issues
Abeona Therapeutics reported Q2 revenues of $11.4 million, falling short of analyst expectations and causing a 14% drop in its stock price. The company treated five patients with its drug Zevaskyn for recessive dystrophic epidermolysis bullosa but fa...
